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Abstract
In randomised trials, continuous endpoints are often measured with some degree of error. This study
explores the impact of ignoring measurement error, and proposes methods to improve statistical in-
ference in the presence of measurement error. Three main types of measurement error in continuous
endpoints are considered: classical, systematic and differential. For each measurement error type, a
corrected effect estimator is proposed. The corrected estimators and several methods for confidence
interval estimation are tested in a simulation study. These methods combine information about error-
prone and error-free measurements of the endpoint in individuals not included in the trial (external
calibration sample). We show that if measurement error in continuous endpoints is ignored, the treat-
ment effect estimator is unbiased when measurement error is classical, while Type-II error is increased
at a given sample size. Conversely, the estimator can be substantially biased when measurement error
is systematic or differential. In those cases, bias can largely be prevented and inferences improved upon
using information from an external calibration sample, of which the required sample size increases as
the strength of the association between the error-prone and error-free endpoint decreases. Measurement
error correction using already a small (external) calibration sample is shown to improve inferences and
should be considered in trials with error-prone endpoints. Implementation of the proposed correction
methods is accommodated by a new software package for R.
Keywords: measurement error, continuous endpoints, bias, correction methods, clinical trials
1 Introduction
In randomised controlled trials, continuous endpoints are often measured with some degree of
error. Examples include trial endpoints that are based on self-report (e.g. self-reported physical
activity levels [1]), endpoints that are collected as part of routine care (e.g. in pragmatic trials
[2]), endpoints that are assessed without blinding the patient or assessor to treatment alloca-
tion (e.g. in surgical [3] or dietary [4] interventions) and an alternative endpoint assessment that
substitutes a gold-standard measurement because of monetary or time constraints or ethical con-
siderations (e.g. food frequency questionnaire as substitute for doubly-labelled water to measure
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energy intake [5]). In these examples, the continuous endpoint measurements contain error in the
sense that the recorded endpoints do not unequivocally reflect the endpoint one aims to measure.
Despite calls for attention to the issue of measurement error in endpoints (e.g. [6]), develop-
ments and applications of correction methods for error in endpoints are still rare [7]. Specifically,
methodology that allow for correction of study estimates for the presence of measurement error
have so far largely been focused on the setting of error in explanatory variables, which may give
rise to inferential errors such as regression dilution bias [8, 9, 10, 11, 12, 13]. In addition, the
application of correction methods for measurement errors in the applied medical literature is
unusual [14, 15].
We provide an exploration of problems and solutions for measurement error in continuous trial
endpoints. For illustration of the problems and solutions for measurement error in continuous
endpoints we consider one published trial that examined the efficacy and tolerability of low-
dose iron-supplements during pregnancy [16]. To test the effect of the iron supplementation on
maternal haemoglobin levels, haemoglobin concentrations were measured at delivery in venous
blood.
This paper describes a taxonomy of measurement errors in trial endpoints, evaluates the ef-
fect of measurement errors on the analysis of trials and tests existing and proposes new methods
evaluating trials containing measurement errors. Implementation of the proposed measurement
error correction methods (i.e. the existing and novel methods) are supported by introducing
a new R package mecor, available at: www.github.com/LindaNab/mecor. This paper is struc-
tured as follows. In section 2 we revisit the example trial introduced in the previous paragraph.
Section 3 presents an exploration of the influence of measurement error structures and their
impact on inferences of trials. In section 4 measurement error correction methods are proposed.
A simulation study investigating the efficacy of the correction methods is presented in section
5. Conclusions and recommendations resulting from this study are provided in section 6.
2 Illustrative example: measurement of haemoglobin levels
Makrides et al. [16] tested the efficacy of a 20-mg daily iron supplement (ferrous sulfate) on
maternal iron status in pregnant women in a randomized, two-arm, double-blind, placebo-
controlled trial. Respectively, 216 and 214 women were randomized to the iron supplement
and placebo arm. At delivery, a 5-mL venous blood sample was collected from the women to
assess haemoglobin levels as a marker for their iron status. Haemoglobin levels of women in
the iron supplement arm were significantly higher than haemoglobin levels of women in the
placebo arm (mean difference 6.9 CI (4.4; 9.3)). Haemoglobin concentrations were measured
spectrophotometrically. Mean haemoglobin values were 137 (SD 3.2) g/L when measured by
certified measurements, compared to mean 135 (SD 0.96) g/L when measured using the equip-
ment used in the trial to measure haemoglobin levels. This might indicate small measurement
errors in the measured haemoglobin levels of the women in the trial. The authors did not discuss
if and how the remaining measurement error if and how could have affected their results.
In this domain, similar trials have been conducted in which the endpoint was assessed with
lower standards. For instance, in field trials testing the effectiveness of iron supplementation,
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capillary blood samples instead of venous blood samples are often used to measure haemoglobin
levels (e.g. [17]). While easier to measure, capillary haemoglobin levels are less accurate than
venous haemoglobin levels [18]. We now discuss how measurement errors in haemoglobin levels
might affect trial inference, by assuming hypothetical differences between capillary and venous
haemoglobin levels. Two more illustrative examples are discussed in supplementary materials
section 1.
2.1 Simulations based on example trial
We expand on the preceding example to hypothetical structures of error in measurement of the
endpoints by simulation. These structures are only explained intuitively (explicit definitions are
provided in section 3). For this example, we take the observed mean difference in haemoglobin
levels in the two groups of the iron supplementation trials as a reference (6.9 g/L higher in the
iron-supplemented group), and assume that haemoglobin levels are normally distributed with
equal variance in both groups (SD 12.6 g/L). Fifty-thousand simulation samples were taken with
54 patients in each treatment arm. The number of patients differed from the 430 patients in the
original trial to yield a Type-II error of approximately 20% in the absence of measurement error
at the usual alpha level (5%). Treatment effect for each simulation sample (mean difference in
haemoglobin levels between the two arms) was estimated by OLS regression.
2.1.1 Classical measurement error in example trial
In the context of measurement of haemoglobin levels, random variability in the haemoglobin
levels of capillary blood samples may be expected to vary more than haemoglobin levels in ve-
nous blood [18], independently of the true haemoglobin level and allocated treatment. Increased
Type-II error is a well-known consequence of endpoints measured by the lower standard that
are unbiased but more variable than the endpoints measured by the preferred measurement
instruments [13]. This form of measurement error is commonly described as “random measure-
ment error” or “classical measurement error” [10]. To simulate such independent variation, we
arbitrarily increased the standard deviation of haemoglobin levels by 75% (from 12.6 to 22.05).
This is equivalent to adding a term drawn from a normal distribution with mean 0 and standard
deviation 18.1 to each endpoint. The impact of this imposed classical error was an increased
between-replication variance of the estimated treatment effects of approximately 55% (left plot
in panel b, Figure 1). The average estimated effect across simulations (depicted by the dashed
line) is approximately equal to the true effect (depicted by the solid line), suggesting the classical
measurement error did not introduce a bias in the estimated treatment effect (a formal proof is
given in section 3.1). Type-II error increased (to 38%) (grey area in Figure 1, panel b) while
Type-I error remained at the nominal level (at 5%, illustrated by the red area in Figure 1, panel
b).
2.1.2 Systematic measurement error in example trial
It may alternatively be assumed that capillary haemoglobin levels are systematically different
from venous haemoglobin levels. This systematic difference can be either additive or multiplica-
tive. For additive systematic measurement error, the capillary haemoglobin levels differ from
venous haemoglobin levels with a certain constant, independently of venous haemoglobin levels.
3
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This implies that in both treatment groups mean haemoglobin level is higher, but that the dif-
ference between the two treatment groups is unbiased. The term systematic measurement error
is often used to indicate multiplicative measurement error [19]. In that case, the expected capil-
lary haemoglobin levels are equal to venous haemoglobin levels multiplied by a certain constant.
Consequently, haemoglobin levels in capillary blood are more accurately measured in patients
with low venous haemoglobin levels than in patients with high true haemoglobin levels (or vice
versa). Under the assumption of a non-zero treatment effect, the expected difference between
mean haemoglobin levels between the two treatment groups is biased; in the absence of a treat-
ment effect, the expected difference between the two groups will remain unaffected. To simulate,
we assumed that capillary haemoglobin levels are 1.05 times haemoglobin levels and we increased
the standard deviation of haemoglobin levels by 75%, equivalent to the previous example. The
impact of this imposed systematic measurement error structure is that the average treatment
effect was biased, increasing from 6.9 to 7.2, and that there is an increased between-replication
variance of the estimated treatment effect of approximately 66% (left plot in Figure 1, panel c).
Type-II error increased (to 37%) (grey area in Figure 1, panel c) while Type-I error remained
at rate close to nominal level (at 5%) (red area in Figure 1, panel c).
2.1.3 Differential measurement error in example trial
The measurement error (structure) may also differ between the treatment arms. In an extreme
scenario, haemoglobin levels in placebo group patients would be measured by venous blood
samples while patients in active arm (iron supplemented) would be measured using capillary
blood samples. To simulate such a scenario, we assume the same systematic error structure from
the previous paragraph, now only applying to the active group. Additionally, we assume classical
measurement error in the placebo group. This scenario classifies as differential measurement error
[7]. The impact of this measurement error structure is that the average treatment effect was
biased, increasing from 6.9 to 13.3, and that the between-replication variance of the estimated
treatment effect is increased by approximately 62% (left plot in Figure 1, panel d). Type-II error
decreased (to 0.1%) (grey area in Figure 1, panel d) and Type-I error rates increased (to 48%)
(red area in Figure 1, panel d).
3 Measurement error structures
Consider a two-arm randomized controlled trial that compares the effects of two treatments
(X ∈ {0, 1}), where 0 may represent a placebo treatment or an active comparator. Let Y
denote the true (or preferred) trial endpoint and Y ∗ an error prone operationalisation of Y .
We will assume that both Y and Y ∗ are measured on a continuous scale. We assume a linear
regression model for the endpoint Y :
Y = αY + βYX + ε, (1)
where ε is iid normally distributed with mean 0 and variance σ2. Under these assumptions and
assumptions about the model for Y ∗ (described below), simple formulas for the bias in the OLS
estimator of the treatment effect can be derived. Details of these derivations can be found in
the supplementary materials, section 2.
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Fig. 1: Illustration of impact of hypothetical measurement error in example trial 1 [16]: (a) no
measurement error; (b) classical measurement error; (c) systematic measurement error;
(d) differential measurement error. The left plots depict every thousandth estimated
OLS regression line (grey lines), the average estimated treatment effect (dashed line) and
the true effect (black line). The right plots depict the density distribution of the Wald
test-statistic of the slope of the regression line, under the null hypothesis of no effect (red
distribution) and the alternative hypothesis of any effect (black distribution).
5
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3.1 Classical measurement error
There is classical measurement error in Y ∗ if Y ∗ is an unbiased proxy for Y [10]: Y ∗ = Y + e,
where e has mean 0 and Var(e) = τ 2 and e independent of Y , X, ε in (1). Using Y ∗ instead of
Y in the linear model yields:
Y ∗ = α∗Y + β
∗
YX + δ, (2)
Where β∗Y = βY and the residuals δ have mean 0 and variance σ
2
δ = σ
2 + τ 2. This leads to a
larger variance in βˆ∗Y (the estimator for β
∗
Y ) compared to the variance in βˆY (the estimator for
βY ). Consequently, classical measurement error will not lead to bias in the effect estimator but
will increase Type-II for a given sample size.
3.2 Heteroscedastic measurement error
In the above we assumed that the variance in e is equal in both arms. When this assumption
is violated, there is so called heteroscedastic measurement error. Heteroscedastic error will not
lead to bias in the effect estimator, but will invalidate the estimator of the variance of βˆ∗Y (proof
is given in supplementary materials section 2).
3.3 Systematic measurement error
There is systematic measurement error in Y ∗ if Y ∗ depends systematically on Y : Y ∗ = θ0 +
θ1Y + e, where e has mean 0 and Var(e) = τ
2 and e independent of Y , X, ε in (1). Throughout,
we assume systematic measurement error if θ0 6= 0 or θ1 6= 1 (and of course, θ1 6= 0 in all cases).
We assume independence between e and Y , X, ε in (1). Using Y ∗ with systematic measurement
error in the linear model yields in the model defined by (2) where β∗Y = θ1βY and the residuals
δ have mean 0 and variance σδ = θ
2
1σ
2 + τ 2. Depending on the value of θ1, the variance of βˆ∗Y is
larger or smaller than the variance of βˆY . Hence, Type-II error will either decrease or increase
under systematic measurement. Type-I error is unaffected since if βY = 0, β
∗
Y = 0 (i.e., tests for
null effects are still valid under systematic measurement error) (proof is given in supplementary
materials section 2).
3.4 Differential measurement error
There is differential measurement error in Y ∗ if Y ∗ depends systematically on Y varying for X:
Y ∗ = θ00 + (θ01− θ00)X+ θ10Y + (θ11− θ10)XY + eX , where eX has mean 0 and Var(e) = τ 2X and
eX independent of Y , and ε in (1) for X = 0, 1. Using Y
∗ with differential measurement error in
the linear model yields in the model defined in (2) where β∗Y = θ01− θ00 + (θ11− θ10)αY + θ11βY
and the residuals δ have mean 0 and variance
[
θ210 + (θ
2
11 − θ210)X
]
σ2 + τ 2X for X = 0, 1. Since
the residual variance is not equal in both arms, the estimator of the variance of βˆ∗Y is invalid,
and will underestimate the true variance. A heteroscedastic consistent estimator of the variance
of βˆ∗Y is provided by the White estimator [20]. Assuming that the White estimator is used to
estimate the variance of βˆ∗Y , Type-I error is not expected the nominal level (α) and Type-II
error will decrease or increase under the differential measurement error model (proof is given in
supplementary materials section 2).
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4 Correction methods for measurement error in a continuous trial
endpoint
In this section we describe several approaches to address measurement error in the trial end-
point. Throughout, we assume that Y ∗ is measured for all i = 1, . . . , N randomly allocated
patients in the trial. We also assume that Y and Y ∗ are both measured for a smaller set of
different individuals not included in the trial (j = 1, . . . , K,K < N), hereinafter referred to
as the external calibration sample. In all but one case, it is assumed that only Y ∗ and Y are
measured in the external calibration sample. In the case that the error in Y ∗ is different for
the two treatment groups, it is assumed that the external calibration sample is in the form of a
small pilot study where both treatments are allocated (i.e., Y ∗ and Y are both measured after
assignment of X). Instead of external calibration data, we could use internal calibration data
to correct for measurement error (Y and Y ∗ are both measured in a small subset of the trial),
which is not considered in this paper as it was studied elsewhere [7].
A well-known consequence of classical measurement error in a continuous trial endpoint is that
a larger sample size (as compared to the same situations without the measurement error) is
needed to compensate for the reduced precision [13]. For example, the new sample size N∗ may
be calculated by N/R formula where R is the reliability coefficient and N the original sample
size for the trial [21]. For solutions for heteroscedastic measurement error, we refer to standard
theory of dealing with heteroscedastic errors in regression to find an unbiased estimator for the
variance of βˆY ∗ (e.g. see [20] for an overview of different heteroscedasticity consistent covariance
matrices).
Hereinafter we focus on measurement error in Y ∗ that is either systematic or differential, both
of which have been shown to introduce bias in the effect estimator if measurement error is ne-
glected (section 3). Consistent estimators for the intervention effects are introduced, and various
methods for constructing confidence intervals for these estimators are discussed. Section 3 in the
supplementary materials provides an explanation of the results stated in this section. Through-
out, we assume that Y ∗ is measured for all i = 1, . . . , N patients in the trial. We also assume
that Y and Y ∗ are both measured for a smaller set of different individuals not included in the
trial (j = 1, . . . , K,K < N), hereinafter referred to as the external calibration sample. For an
earlier exploration of the use of an internal calibration set when there is systematic or differential
measurement error in endpoints, see [7].
4.1 Systematic measurement error
From section 3.3 it follows that natural estimators for αY and βY are
αˆY = (αˆY ∗ − θˆ0)/θˆ1 and βˆY = βˆY ∗/θˆ1, (3)
Where θˆ0 and θˆ1 are the estimated error parameters from the calibration data set using standard
OLS regression. From equation (3), it becomes apparent that θˆ1 needs to be assumed bounded
away from zero for finite estimates of αˆY and βˆY [8]. The estimators in (3) are consistent, see
for a proof section 3.1 in the supplementary materials.
The variance of the estimators defined in (3) can be approximated using the Delta method [22],
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the Fieller method [22], the Zero-variance method and by bootstrap [23]. Further details are
provided in section 3.1 of the supplementary materials.
4.2 Differential measurement error
From section 3.4 it follows that natural estimators for αY and βY are,
αˆY = (αˆY ∗ − θˆ00)/θˆ10 and βˆY = (βˆY ∗ + αˆY ∗ − θˆ01)/θˆ11 − αˆY , (4)
where θˆ00, θˆ10, θˆ01 and θˆ11 are estimated from the external calibration set using standard OLS
estimators. Here it is assumed that both θˆ10 and θˆ11 are bounded away from zero (for reasons
similar to those mentioned in section 4.1). The estimators in (4) are consistent, see for a proof
section 3.1 of the supplementary materials. The variance of the estimators defined in (4) can
be approximated using the Delta method [22], the Zero-variance method and by bootstrap [23].
Further details are provided in section 3.2 of the supplementary materials.
5 Simulation study
The finite sample performance of the measurement error corrected estimators of the treatment
effect was studied by simulation. We focussed on the situation of a two-arm trial in which the
continuous surrogate endpoint Y ∗ was measured with systematic or differential measurement
error, and in which an external calibration set was available, which was varied in size. The
results from example trial 1 are used to motivate our simulation study (see section 2).
5.1 Data generation
Data were generated for a sample of N = 400 individuals, approximately equal to the size of
example trial 1 [16]. The individuals were equally divided in the two treatment arms. The
true endpoints were generated according to model (1), assuming iid normal errors, and using the
estimated characteristics found in example trial 1 (αY = 120, βY = 6.9 and σ = 12.6). Surrogate
endpoints Y ∗ were generated under models for systematic measurement error and differential
measurement error described in section 3.3 and 3.4, respectively.
For systematic measurement error in Y ∗, we set θ0 = 0 and θ1 = 1.05. Under the differen-
tial measurement error model we set θ00 = 0, θ01 = 0, θ10 = 1, θ11 = 1.05. We considered
three scenarios based on the coefficient of determination between the Y ∗ and Y , R2Y ∗,Y : (i)
R2Y ∗,Y = 0.8, (ii) R
2
Y ∗,Y = 0.5 and (iii) R
2
Y ∗,Y = 0.2. This large range in coefficient of determi-
nation values reflects the wide variation we anticipate in practice from very strong correlations
between Y ∗ and Y (R2Y ∗,Y = 0.8) to weak correlations (R2Y ∗,Y = 0.2), as for example, one could
expect in the context of trials with dietary intake as endpoints [7, 24]. For R2Y ∗,Y = 0.8, τ = 6.6
for systematic measurement error and τ0 = 6.3 and τ1 = 6.6 for differential measurement error.
For R2Y ∗,Y = 0.5, τ = 13.2 for systematic measurement error and τ0 = 12.6 and τ1 = 13.2 for
differential measurement error. For R2Y ∗,Y = 0.2, τ = 26.5 for systematic measurement error
and τ0 = 25.2 and τ1 = 26.5 for differential measurement error. Additionally, we considered a
scenario with greater systematic measurement error holding θ0 = 0 and θ1 = 1.25. Here, we only
studied a high coefficient of determination R2Y ∗,Y = 0.8, implying that τ = 7.9.
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For the scenarios with systematic measurement error induced, a separate calibration set was
generated of size K with the characteristics of the placebo arm for each simulated data set.
For differential measurement error scenarios, a calibration data set was generated of size K
for each simulated data set, with K0 = K1 = K/2 subjects equally divided over the two
treatment groups. The sample size of the external calibration data set (K) was varied with
K ∈ {5, 7, 10, 15, 20, 30, 40, 50} for systematic measurement error and K ∈ {10, 20, 30, 40, 50}
for differential measurement error.
5.2 Computation
For each simulated data set the corrected treatment effect estimator (3) for systematic error and
(4) for differential error were applied. In systematic measurement error scenarios, confidence
intervals for the corrected estimator for α = 0.05 were constructed by using the Zero-variance
method, the Delta method, the Fieller method, and the Bootstrap method based on 999 replicates
(as defined in section 4.1). In the case of differential measurement error, confidence intervals for
the corrected estimator for α = 0.05 were constructed by using the Zero-Variance method, the
Delta method and the Bootstrap method based on 999 replicates (as defined in section 4.2). The
HC3 heteroscedastic consistent variance estimator was used to accommodate for heteroscedastic
error in the differential measurement error scenario [20]. Furthermore, for both the systematic
and differential measurement error scenarios the naive analysis was performed (resulting in a
naive effect estimate and naive confidence interval), which is the ’regular’ analysis which would
be performed if measurement errors were neglected.
We studied performance of the corrected treatment effect estimators in terms of percentage bias
[25], empirical standard error (EmpSE) and square root of the mean squared error (SqrtMSE)
[26]. The performance of the methods for constructing the confidence intervals was studied in
terms of coverage and Type-II error [26].
In our simulations, the Fieller method resulted in undefined confidence intervals if in an it-
eration θˆ1/
√
t2/S
(c)
yy > tN−2. The percentage of iterations for which the Fieller method failed
to construct confidence intervals is reported. If the Fieller method resulted in undefined confi-
dence intervals in more than 5% of cases in one simulation scenario, the coverage and average
confidence interval width were not calculated as this would result in unfair comparisons between
the different confidence interval constructing methods. The bootstrap confidence intervals were
based on less than 999 estimates in case the sample drawn from the external calibration set
consisted of K equal replicates. These errors occurred more frequently for small values of K
and low R-squared. All simulations were run in R version 3.4, using the library mecor (version
0.1.0). The results of the simulation are available at doi.org/10.6084/m9.figshare.7068695 and
the code is available at doi.org/10.6084/m9.figshare.7068773, together with the seed used for the
simulation study.
5.3 Results of simulation study
5.3.1 Systematic measurement error
Table 1 shows percentage bias, EmpSE and SqrtMSE of the naive estimator and the corrected
estimator for θ1 = 1.25 and R
2
Y ∗,Y = 0.8 and θ1 = 1.05 and R
2
Y ∗,Y = 0.8, R
2
Y ∗,Y = 0.5 and
9
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R2Y ∗,Y = 0.2 and K ∈ {5, 7, 10, 15, 20, 30, 40, 50} when there is systematic measurement error.
Naturally, the percentage of bias in the naive estimator is about 5% if θ1 = 1.05 and 25% if
θ1 = 1.25. For the corrected estimator and θ1 = 1.05 or θ1 = 1.25 and R
2
Y ∗,Y = 0.8, percentage
bias, EmpSE and SqrtMSE of βˆY are reasonably small for K ≥ 10. Yet, as the bias in the naive
estimator is small when θ1 = 1.05, SqrtMSE of the corrected estimator is never lower than the
SqrtMSE of the naive estimator. However, if bias in the naive estimator is greater (θ1 = 1.25),
SqrtMSE of the corrected estimator is smaller than SqrtMSE of the naive estimator for K ≥ 15.
For the corrected estimator and θ1 = 1.05 and R
2
Y ∗,Y = 0.5, bias is reasonably small for K ≥ 30.
Nevertheless, SqrtMSE of the corrected estimator is always greater than SqrtMSE of the naive
estimator. For the corrected estimator and θ1 = 1.05 and R
2
Y ∗,Y = 0.2, bias of βˆY fluctuates
and EmpSE and SqrtMSE is large for all K ′s. The estimates of the intervention effect using the
corrected estimator of each 10th iteration of our simulation is shown in Figure 2, which provides
a clear visualization of the results formerly discussed. The bigger the sample size of the external
calibration set and the higher R-squared, the better the performance of the corrected estimator.
The sampling distribution of θˆ1 depicted in Figure 3 explains why there is so much variation
in the corrected effect estimator for small sample sizes of the external calibration set and low
R-squared. Namely, for a number of iterations in our simulation, θˆ1 was estimated close to zero,
expanding the corrected estimator the same number of times resulting in large bias, EmpSE
and MSE. Note that if θˆ1 < 0, the sign of the corrected estimator changes, explaining why the
corrected estimate of the intervention effect is sometimes below zero.
For R2Y ∗,Y = 0.8 and both θ1 = 1.05 and θ1 = 1.25, the Fieller method failed to construct
confidence intervals in 15, 5, 1 and 0.1 % of simulated datasets for respectively K = 5, 7, 10, 15.
Therefore, coverage and average confidence interval width of the Fieller method is not evaluated
for K ∈ {5, 7}. For R2Y ∗,Y = 0.5, the Fieller method failed to construct confidence intervals in
48, 36, 22, 8, 3, 0.3 % of simulated data sets for K ∈ {5, 7, 10, 15, 20, 30}, respectively. Conse-
quently, coverage and average confidence interval width is not evaluated for K ∈ {5, 7, 10, 15}.
For R2Y ∗,Y = 0.2, the Fieller method failed to construct confidence intervals in 74, 71, 64, 53, 43,
26, 15 and 8 % of simulated data sets for K ∈ {5, 7, 10, 15, 20, 30, 40, 50}, respectively (i.e., in
every case more than 5%, thus the Fieller method is not evaluated for R2Y ∗,Y = 0.2).
Table 1 shows coverage of the true intervention effect in the constructed confidence intervals
and average confidence interval width using the Zero-variance, Delta, Fieller and Bootstrap
method. Using Wald confidence intervals for the naive effect estimator nearly yielded 95%
coverage of the true treatment effect of 6.9, because for θ1 = 1.05 the bias percentage in the
naive estimator is small (i.e., 5%). Yet, as bias percentage increased in the naive estimator for
θ1 = 1.25 (i.e., 25%) coverage dropped to 83.5%. The Zero-variance method yielded too narrow
confidence intervals for all scenario’s, an intuitively clear result as the Zero-variance method ne-
glects the variance in θˆ1. For R
2
Y ∗,Y = 0.8 the Delta, Fieller and Bootstrap method constructed
correct confidence intervals for K ≥ 15. For K ≤ 10 the Delta method and the Fieller method
constructed too narrow confidence intervals, and the Bootstrap method too broad confidence
intervals. For R2Y ∗,Y = 0.5 the Delta and Bootstrap method constructed correct confidence in-
tervals for K ≥ 30. For K ≤ 20 the Delta method constructed too narrow confidence intervals,
and the Bootstrap method too broad confidence intervals. Coverage of the Fieller method was
about the desired 95% level for K ≥ 30.
10
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Using the naive effect estimator, Type-II error was 0.2%, 2.9% and 31.6% for R2Y ∗,Y = 0.8
(both for θ1 = 1.05 and θ1 = 1.25), R
2
Y ∗,Y = 0.5 and R
2
Y ∗,Y = 0.2, respectively. Type-II error
in the corrected estimator using the Zero-variance, Delta and Boostrap method was 0%. For
the considered scenario’s using the Fieller method, Type-II error was 0.02% for R2Y ∗,Y = 0.8 and
2.9% for R2Y ∗,Y = 0.5.
5.3.2 Differential measurement error
Table 2 shows percentage bias, EmpSE and SqrtMSE of the naive estimator and the corrected
estimator for R2Y ∗,Y = 0.8, R
2
Y ∗,Y = 0.5 and R
2
Y ∗,Y = 0.2 and K ∈ {5, 7, 10, 15, 20, 30, 40, 50}
when there is differential measurement error. The percentage bias in the naive estimator was
about 92%. For the corrected estimator and R2Y ∗,Y = 0.8, percentage bias, EmpSE and SqrtMSE
of βˆY are reasonably small for K ≥ 20. For the naive estimator and R2Y ∗,Y = 0.5, percentage
bias, EmpSE and MSE of the corrected estimator are small for K = 50. For the naive estimator
and R2Y ∗,Y = 0.2, percentage bias, EmpSE and MSE of the corrected estimator is large for all
K’s. The estimates of the intervention effect using the corrected estimator of each 10th iteration
of our simulation is shown in Figure 4, which provides a clear visualization of the results formerly
discussed. The bigger the sample size of the external calibration set and the higher R-squared,
the better the performance of the corrected estimator.
Table 2 shows coverage of the true intervention effect in the constructed confidence intervals
and average confidence interval width using the Zero-Variance, Delta and Bootstrap method.
Coverage of the true treatment effect of 6.9 using Wald confidence intervals for the naive effect
estimator were about 1%, 7% and 41% for R2Y ∗,Y = 0.8, R
2
Y ∗,Y = 0.5 and R
2
Y ∗,Y = 0.2, respec-
tively. In all cases, the Zero-Variance method yielded too narrow confidence intervals; the Delta
method yielded too broad confidence intervals and the Bootstrap method yielded mostly too
broad confidence intervals, except for R2Y ∗,Y = 0.8 and K = 30 and K = 40 (too narrow). For
R2Y ∗,Y = 0.8 and K = 50, coverage of the true intervention effect was 95%.
Type-II error in the naive effect estimator was 0%, 0% and 0.4% for R2Y ∗,Y = 0.8, R
2
Y ∗,Y = 0.5 and
R2Y ∗,Y = 0.2, respectively. Type-II error in the corrected effect estimator using the Zero-variance,
Delta and Bootstrap method was 0%.
5.4 Measurement error dependent on a prognostic factor
Above, we focused on measurement errors in endpoints that are either systematic (linearly de-
pendent on true endpoint) or differential (linearly dependent on true endpoint and exposure).
Yet, measurement error could depend on prognostic factors. For example, measurement error in
haemoglobin levels measured in capillary blood may differ for women and men [18]. Moreover,
haemoglobin levels are, on average, higher in men than women. To illustrate the effect of mea-
surement error that is dependent on a prognostic factor, we use example trial 1, here assuming
that it was conducted in women and men. Data were generated for a sample of N = 400 individ-
uals, equally divided in two treatment arms and with equal sex distribution in both arms. Let
the proportion of women in the sample be 75% (S = 1 for men and S = 0 for women). Further,
assume Y = 120 + 6.9X + 10S + ε, where ε has mean 0 and Var(ε) = 158.8. Additionally,
assume additive systematic measurement error in Y ∗, Y ∗ = Y + 0.5S + e (additive systematic
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Fig. 2: Estimates of the treatment effect using the naive estimator and corrected estimator for
different values of R-squared (row grids) and different sample sizes of the external cali-
bration set (column grids) under systematic measurement error (θ1 = 1.05 (0.2; 0.5; 0.8a)
or θ1 = 1.25 (0.8b)). Each grid is based on every 10th estimate of a simulation of 10,000
replicates, using an estimand of 6.9 (indicated by the red line), based on example trial 1
by Makrides et al. [16].
measurement error in men and random measurement error in women), where e has mean 0 and
Var(e) = 6.6 and e independent of Y , X, S and ε. In a simulation of 10,000 replicates we
estimated the effect of Y ∗ on X (naive analysis) and the effect of Y ∗ on X, conditional for S
(conditional analysis). In section 4 of the supplementary materials, we proof that both analyses
will result in correct estimation of the treatment effect. The results of the simulation study show
that the average treatment effect estimate of both analyses was 6.89, indicating that there is no
bias in either of the analyses. Yet, the empirical variance of the effect estimate in the 10,000
replicates was somewhat lower for the conditional analysis compared to the naive analysis (2.01
vs. 2.22), indicating an efficiency gain in favor of the conditional analysis. By assuming that
randomisation was well-performed, measurement error dependent on a prognostic factor does
not introduce bias in the naive analysis other than the biases already discussed.
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Fig. 3: Estimates of θ1 (i.e. slope of the systematic measurement error model) for different values
of R-squared (row grids) and different sample sizes of the external calibration set (column
grids). Each grid is based on every 10th estimate of a simulation of 10,000 replicates,
using an estimand of 1.05 (indicated by the red line).
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Fig. 4: Estimates of the treatment effect using the naive estimator and corrected estimator for
different values of R-squared (row grids) and different sample sizes of the external calibra-
tion set (column grids) under differential measurement error (θ00 = 0, θ10 = 1, θ01 = 0,
θ11 = 1.05). Each grid is based on every 10th estimate of a simulation of 10,000 repli-
cates, using an estimand of 6.9 (indicated by the red line), based on example trial 1 by
Makrides et al. [16].
14
L Nab, RHH Groenwold, PMJ Welsing, M van Smeden 15
6 Discussion
This paper outlined the ramifications for randomised trial inferences when a continuous endpoint
is measured with error. Our study showed that when this measurement error is ignored, not
only can trial results be hampered by a loss in precision of the treatment effect estimate (i.e.
increased Type-II error for a given sample size), but trial inferences can be impacted through
bias in the treatment effect estimator and a null-hypothesis significance test for the treatment
effect can deviate substantially from the nominal level. In this article we proposed a number of
regression calibration-like correction methods to reduce the bias in the treatment effect estimator
and obtain confidence intervals with nominal coverage. In our simulation studies, these methods
were effective in improving trial inferences when an external calibration dataset (containing in-
formation about error-prone and error-free measurements) with at least 15 subjects was available.
To anticipate the impact of measurement error on trial inferences, the mechanism and magni-
tude of the measurement error should be considered. Endpoints that are measured with purely
homoscedastic classical measurement error are expected to reduce the precision of treatment
effect estimates and increase Type-II error at a given sample size, proportional to the relative
amount of variance that is due to the error. Heteroscedastic classical error and differential error
also affect Type-I error. Under systematic measurement error, only Type-I errors for testing null
effects are expected to be at the nominal level. The treatment effect estimator itself is biased by
systematic error and differential error. Heteroscedastic error can be addressed using standard
robust standard error estimators (e.g. HC3 [20]). Systematic error and differential error in the
endpoint can be addressed via regression calibration.
We considered regression calibration-like correction methods that rely on an external calibra-
tion set that contains information about both error-prone and error-free measurements. We
anticipate such an external calibration set can be feasible as a planned pilot study phase of a
trial. Our simulation study shows that the effectiveness of correction methods to adjust the trial
results for endpoint measurement error are dependent on the size of the calibration sample and
the strength of the correlation between the error-free and error-prone measurement of the trial
endpoint. For a weak relation (R2 = 0.20) we found the correction methods to be generally
ineffective in improving trial inference with reasonably sized calibration sets (i.e., up to size N
= 50). However, for medium (R2 = 0.50) or strong (R2 = 0.80) correlations, the regression
calibration showed improvements with external calibration samples as small as 15 observations.
With the relatively small calibration samples (up to 50 observations), our study showed that
the Bootstrap method performed best in constructing confidence intervals in terms of coverage.
The use of percentiles might explain that confidence intervals were slightly conservative (i.e. too
broad) for small calibration samples (10 observations), and might be improved by using bias-
corrected and accelerated Bootstrap intervals [27]. The proposed calibration correction methods
rely on a linear regression framework and can thus easily be extended to incorporate covariables
in the trial analysis [28].
The use of measurement error corrections is still rare in applied biomedical studies despite
an abundance of measurement error problems usually reported as an afterthought to a study
[14, 15]. Indeed, to our knowledge, no measurement error correction methods have been used
so far in the analysis of biomedical trials to correct for measurement error in the endpoint.
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This may in part be due to a common misconception that measurement error can only affect
trial inference by reducing the precision of estimating the effect of treatment and increasing
Type-II error, which can be improved by increasing the study sample size. Note that our study
demonstrates that such an assumption is warranted only when strict classical homoscedastic
error structure of the trial endpoint can be assumed. Such does not hold, for instance, when
measurement errors are more pronounced in the tails of the distribution, or when measurement
errors vary between treatment arms.
Instead of the use of external calibration datasets, internal measurement correction approaches
where both the preferred endpoint and the error contaminated endpoint are measured on a
subset of trial participants may sometimes be more feasible. For internal calibration, Keogh et
al. [7] recently reviewed methods of moment estimation and maximum likelihood estimation
approaches. There are also other approaches to correct for measurement error that we did not
discuss in this paper. For instance, Cole and colleagues suggested a multiple imputing approach
based on an internal calibration set [29]. We also focused only on continuous outcomes in this
paper. Problems and solutions for misclassified categorical outcomes can be found elsewhere
[30]. Yet, to the best of our knowledge, none of these methods have been tested in the setting
where trial endpoints are measured with error and thus need further study.
Lastly, we solely discuss parametric measurement error models, which might misspecify the
measurement error model. The extent to which the distribution of the unmeasured outcome can
be estimated without parametric assumptions is a question for further research. In the context
of measurement error in explanatory variables this is formerly described as deconvolution ([10],
Chapter 12 and references therein). Further, the method of non-parametric maximum likeli-
hood has been successfully applied for explanatory variables measured with error [31, 32] and
this might be an avenue of future research.
In summary, the impact of measurement error in a continuous endpoint on trial inferences
can be particularly non-ignorable when the measurement error is not strictly random, because
Type-I error, Type-II and the effect estimates can be affected. To alleviate the detrimental
effects of measurement error we proposed measurement error corrected estimators and a variety
of methods to construct confidence intervals for non-random measurement error. To facilitate
the implementation of these measurement error correction estimators we have developed the R
package mecor, available at: www.github.com/LindaNab/mecor.
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Tab. 1: Percentage bias, Empirical Standard Error (EmpSE), Squared root of Mean Squared
Error (SqrtMSE), Coverage and average width of CI’s of the naive estimator and the
corrected estimator for systematic measurement error (θ0 = 0 and θ1 = 1.05 or
θ1 = 1.25) for different values of R-squared and different sample sizes of the calibration
data set. Each scenario is based on 10,000 replicates, the value of the estimand is 6.9,
based on example trial 1 by Makrides et al. [16]
Measure∗ R2Y ∗,Y θ1 Sample size external calibration set
Naive 5 7 10 15 20 30 40 50
Percentage bias (%) 0.8 1.25 24.9 88.9 29 3.7 2 1.6 0.9 0.7 0.4
0.8 1.05 4.9 88.9 29 3.7 2 1.6 0.9 0.7 0.4
0.5 4.9 55.3 57.5 -2.4 7.6 5.8 4.3 3 2
0.2 4.9 168.2 -62.6 98.8 33.4 -142.2 -28.3 23.9 14.6
EmpSE 0.8 1.25 1.8 524.8 139.1 3 1.9 1.7 1.6 1.5 1.5
0.8 1.05 1.5 524.8 139.1 3 1.9 1.7 1.6 1.5 1.5
0.5 1.9 267 329.1 83.7 14.4 11 2.5 2.3 2.1
0.2 3 1131.2 210.8 723.2 462.2 1044.4 225.5 70.5 24.8
SqrtMSE 0.8 1.25 2.5 524.8 139.1 3.1 1.9 1.7 1.6 1.5 1.5
0.8 1.05 1.5 524.8 139.1 3.1 1.9 1.7 1.6 1.5 1.5
0.5 1.9 267 329.1 83.7 14.4 11 2.5 2.3 2.1
0.2 3 1131.2 210.8 723.1 462.2 1044.4 225.5 70.5 24.8
Coverage (%) 0.8 1.25 83.5‡ Zero-Variance 70.3 74 77.4 80.3 82.8 84.4 85.3 86.3
Delta 93.8 95.3 95.7 95.9 96 96 95.9 95.7
Fieller† - - 94.5 94.7 95 95.3 95.2 95
Bootstrap 95.9 96.1 95.5 94.9 94.8 95 95.1 94.8
0.8 1.05 94.6‡ Zero-Variance 77.8 81.3 84.4 87.1 89.2 90.9 92 92.2
Delta 92.1 93.9 94.3 94.8 95.1 95.3 95.4 95.2
Fieller† - - 94.5 94.7 95 95.3 95.2 95
Bootstrap 95.9 96.1 95.5 94.9 94.8 95 95.1 94.8
0.5 94.8‡ Zero-Variance 69.1 73.5 78.1 81.7 84.5 87.5 88.7 89.9
Delta 89.7 92 92.9 93.9 94.3 95.2 95.4 95.3
Fieller† - - 94.5 95.2 95.2 95 94.8 94.9
Bootstrap 93.9 95.9 96.3 95.8 95.4 94.8 94.8 94.8
0.2 95.1‡ Zero-Variance 57.1 64.5 71 76.8 80.3 84.3 86 87.6
Delta 86.8 89.7 90.9 92.2 93.5 94.4 94.6 94.9
Fieller† - - 89.8 93.2 94.9 95.8 95.8 95.7
Bootstrap 88.9 93.8 95.5 96.4 96.7 96.8 96.8 96.1
Av. CI width 0.8 1.25 6.9‡ Zero-Variance 30333 1141.5 5.5 4.7 4.7 4.6 4.5 4.5
Delta 40.7 13.6 8.7 7.5 7 6.5 6.3 6.1
Fieller† - - 11.8 8.3 7 6.4 6.1 6
Bootstrap 86.9 29.3 14.1 8.3 7.1 6.4 6.1 6
0.8 1.05 5.8‡ Zero-Variance 36110.7 1359 6.5 5.6 5.5 5.4 5.4 5.4
Delta 35 12.2 8 7 6.7 6.3 6.1 6
Fieller† - - 11.8 8.3 7 6.4 6.1 6
Bootstrap 86.9 29.3 14.1 8.3 7.1 6.4 6.1 6
0.5 7.4‡ Zero-Variance 7228.9 9759.5 763.1 37.5 17.8 7.7 7.3 7.1
Delta 58.1 43.2 21.2 12.6 11 9.3 8.7 8.4
Fieller† - - 67.9 63.2 25 12.4 9.8 9
Bootstrap 146.8 87.4 65.2 34.7 22.8 12.4 9.9 9
0.2 11.6‡ Zero-Variance 126830.3 11677.5 87123.4 30709.4 324870.7 12430.8 774.6 126.8
Delta 179.3 102.5 112.7 69.9 65.7 34.1 19.7 16.6
Fieller† - - 92.6 95.1 72.1 82.2 60.6 59.2
Bootstrap 176 121.9 126.2 118.7 107.7 77.6 54.8 39.7
∗Monte Carlo standard errors of Bias, EmpSE, MSE and Coverage are subsequently, EmpSE
√
1/10, 000;
EmpSE/(2
√
9, 999);
√∑10,000
i=1 [(βˆi−6.9)2−MSE]2
9,999×10,000 and
√
[Cover.× (1− Cover.)]/10, 000 [26].
†Results of the Fieller method are shown if less than 5% of cases resulted in undefined confidence intervals (see
section 5.2).
‡Coverage of the true intervention effect and average confidence interval width using regular Wald confidence
intervals of the naive effect estimator.
Type-II error using the naive effect estimator is 0.2%, 2.9% and 31.6% for R2Y ∗,Y = 0.8 (for both θ1 = 1.05 and
θ1 = 1.25), R
2
Y ∗,Y = 0.5 and R
2
Y ∗,Y = 0.2, respectively. Type-II error using the corrected effect estimator using
the Zero-Variance, Delta and Bootstrap method was 0% in all scenario’s. For the considered cases, Type-II
error of the corrected effect estimator using the Fieller method was 0.2% and 2.9% for R2Y ∗,Y = 0.8 (for both
θ1 = 1.05 and θ1 = 1.25) and R
2
Y ∗,Y = 0.5, respectively.
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Tab. 2: Percentage bias, Emperical Standard Error (EmpSE), Mean Squared Error (MSE),
Squared root of Mean Squared Error (SqrtMSE), Coverage and average width of CI’s
of the corrected estimator for differential measurement error (θ00 = 0, θ10 = 1, θ01 = 0,
θ11 = 1.05) for the strong and poor proxy and different sample sizes of the calibration
data set. Each scenario is based on 10,000 replicates, the value of the estimand is 6.9,
based on example trial 1 by Makrides et al. [16]
Measure∗ R2Y ∗,Y Sample size external calibration set
Naive 10 20 30 40 50
Percentage bias (%) 0.8 91.8 5.2 1.2 -0.4 -0.2 -0.1
0.5 91.8 -9.7 33 154.2 -21.4 -0.1
0.2 91.9 -319.4 152.9 193.1 -21.5 2.2
EmpSE 0.8 1.4 52 6.8 2.9 2.6 2.3
0.5 1.8 949.1 369.1 1080.4 142.1 4.5
0.2 2.9 2658 8425.8 1569.7 443.7 92.1
SqrtMSE 0.8 6.5 52 6.8 2.9 2.6 2.3
0.5 6.6 949.1 369.1 1080.4 142.1 4.5
0.2 7 2658 8425.4 1569.7 443.7 92.1
Coverage (%) 0.8 0.7‡ Zero-Variance 43.8 59.9 67.9 72.7 76.8
Delta 97.1 96.6 96 95.7 95.9
Bootstrap 97.9 95.7 94.7 94.5 95
0.5 6.7‡ Zero-Variance 30.3 43.3 50.2 55.5 61
Delta 97.6 97.6 97.3 96.9 97
Bootstrap 98.4 98 96.6 95.8 95.5
0.2 41.1‡ Zero-Variance 25.7 35 41.9 46.6 52.2
Delta 98.4 99 98.9 98.9 98.9
Bootstrap 99 99.6 99.2 99 98.7
Av. CI width 0.8 5.7‡ Zero-Variance 8.2 5.9 5.7 5.7 5.6
Delta 2688.7 18.3 12.1 10.5 9.5
Bootstrap 142.6 24.3 13.1 10.7 9.5
0.5 7.2‡ Zero-Variance 33 17.9 30.3 10.6 7.5
Delta 463975.1 49493.3 660587.5 13238 18.5
Bootstrap 303.5 118.8 58.4 34.2 24
0.2 11.4‡ Zero-Variance 64.6 150.5 53.1 43.1 26.8
Delta 1219162.5 26998502.1 486295.4 85139.8 3407.5
Bootstrap 562.9 353.8 283.3 221.4 170.2
∗Monte Carlo standard errors of Bias, EmpSE, MSE and Coverage are subsequently, EmpSE
√
1/10, 000;
EmpSE/(2
√
9, 999);
√∑10,000
i=1 [(βˆi−6.9)2−MSE]2
9,999×10,000 and
√
[Cover.× (1− Cover.)]/10, 000 [26].
‡Coverage of the true intervention effect and average confidence interval width using regular Wald confidence
intervals of the naive effect estimator.
Type-II error of the naive effect estimator was 0%, 0% and 0.4% for R2Y ∗,Y = 0.8, R
2
Y ∗,Y = 0.5 and
R2Y ∗,Y = 0.2, respectively. Type-II error using the Zero-variance, Delta and Bootstrap method was 0%.
21
Supplementary Materials
These are the supplementary materials accompanying the paper ‘Measurement error in continu-
ous endpoints in randomised trials: problems and solutions’ by L. Nab et al. The supplementary
materials are structured as follows. In section 1 we discuss two more example trials for illus-
tration of measurement errors in an endpoint. In section 2 we explain why and under which
assumptions ignoring measurement error will lead to incorrect inference. Section 3 provides
an explanation of corrected effect estimators (and why these are consistent) and explains the
methods used for confidence interval estimation. Section 4 provides a prove that measurement
error depending on prognostic factors does not introduce bias in the treatment effect estimator.
S1 Illustrative examples
We introduce here two additional example trials from literature, hypothesize that these trial
could also have used endpoints measured with error to illustrate how the use of an endpoint that
is contaminated with error would affect trial inference. We assume that the original endpoints
used in our example trials are measurement error free.
S1.1 Example trial 2: energy expenditure
Poehlman and colleagues [33] studied the effects of endurance and resistance training on total
daily energy expenditure in a randomised trial of young sedentary women. Participants were
randomized to one of three six-month during exercise programmes: endurance training, resis-
tance training or the control arm. Some controversy regarding the effect of exercise training on
total energy expenditure (TEE) existed at the time of the start of the trial, partly because of
the difficulty to assess daily energy expenditure [33]. Starting 72 hours after completion of the
training program, TEE of the participants was measured by doubly labelled water during a ten
day period, which is considered the gold standard in measuring energy expenditure in humans
[34]. In short, the study found no evidence for an effect of resistance and endurance training
(compared to placebo) on total energy expenditure. Post-trial, measured TEE was higher in
the control arm than in the two intervention arms. Table 1 shows the decrease in TEE of the
women exposed to the existence training programme versus the placebo arm.
S1.2 Example trial 3: rheumatoid arthritis disease activity
The U-Act-Early trial tested the efficacy of a new treatment strategy for rheumatoid arthritis
(RA) in patients with newly diagnosed RA [35] in a three-arm trial: tocilizumab plus methotrex-
ate versus tocilizumab only versus methotrexate only, all as initial treatment. For endpoint
assessment, this trial used a validated RA disease activity measure (the Disease Activity Score
28, DAS28) [36]) which is commonly used and recommended to measure endpoints in RA clin-
ical trials [37, 38]. In short, the trial showed that immediate initiation of tocilizumab with or
without methotrexate is more effective than methotrexate alone to achieve sustained remission
in newly diagnosed RA patients. The difference in mean DAS28 score in the tocilizumab plus
methotrexate versus methotrexate only group after 24 weeks is shown in Table S1. The sample
size of the former groups reported in Table S1 is based on measurements available at 24 weeks
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Tab. S1: Impact of classical measurement error on Type-II error
Effect estimate Standard error Sample Size ρ‡ Type-II error∗
Trial 1 6.9† 1.27† 393† 0 -
2.43 108 0 20%
2.71 108 1/5 29%
2.45 132 1/5 20%
Trial 2 −246† 369† 35† 0 -
88.7 600 0 20%
109 600 1/3 38%
88.7 900 1/3 20%
Trial 3 −1.4† 0.08† 198† 0 -
0.41 8 0 18%
0.50 8 3/7 41%
0.44 12 3/7 18%
† Effect estimates, standard errors and sample sizes are based on results in papers by Makridis et al. [16] (trial
1), Poehlman et al. [33] (trial 2) and Bijlsma et al. [35] (trial 3).
‡ Proportion of observed variance in endpoints due to measurement error.
∗ Type-II error calculations are based on results provided in section 3.1.
of follow up.
A common alternative approach to measure energy expenditure (example trial 2) is by a ac-
celerometer, that measures body movement via motion sensors to assess energy expenditure (e.g.
[34]). As compared to double labelled water (example trial 2), the accelerometer is cheaper, but
less accurate [34]. Lastly, instead of endpoint assessment by DAS28 (example trial 3), where
assessment is done by trained medical staff [36], trials could alternatively use the patient-based
RA disease activity score (PDAS), where endpoint assessment is done by the patient [39].
For the example trial in the paper and each of the aforementioned example trials here, in Table
S1 we show to what extent the Type-II of a test for treatment effect changes when a hypothetical
lower standard of endpoint measurement would have been used introducing classical measure-
ment error. The table clearly shows the anticipated increase in Type-II error with increasing
error at the same sample size.
S2 Measurement error structures
Consider a two-arm randomized controlled trial that compares the effects of two treatments
(X ∈ {0, 1}), where 0 may represent a placebo treatment or an active comparator. Let Y
denote the true (or preferred) trial endpoint and Y ∗ an error prone operationalisation of Y . We
will assume that both Y and Y ∗ are measured on a continuous scale. Throughout, we assume
that Y ∗ is measured for all i = 1, . . . , N randomly allocated patients in the trial. We assume
that the effect of allocated treatment (X ∈ {0, 1}) on preferred endpoint Y is defined by the
linear model
Y = αY + βYX + ε, (S1)
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where βY defines the treatment effect on the endpoint, and ε has expected mean 0 and variance
σ2. Throughout, we assume that X is fixed. Further, we assume that model S1 is inestimable
from the observed data because the endpoint Y ∗ instead of Y was measured. We will assume
that the relation between Y and Y ∗ is given by a linear model,
Y ∗ = θ0 + θ1Y + e, (S2)
where e is a random variable whose distribution is independent of ε, Y and X. The parameters
θ0 and θ1 define the relation between Y and Y
∗, where it is assumed that θ1 does not equal 0.
We assume that both parameters θ0 and θ1 are estimable only in the external calibration sample
comprising individuals not included in the trial (j = 1, . . . , K).
Simple OLS regression estimators for βY , αY and σ
2 (the variance of the errors ε) in (S1)
are,
βˆY ∗ =
∑
i(Xi − X¯)(Y ∗i − Y¯ ∗)∑
i(Xi − X¯)2
, (S3)
αˆY ∗ = Y¯ ∗ − βˆY ∗X¯, (S4)
ωi = Y
∗
i − αˆY ∗ − βˆY ∗Xi, (S5)
s2 =
1
N − 2
∑
i
ω2i , (S6)
respectively. In a two-arm trial, the interest is in making inferences about βY , which cannot
be directly estimated because in the trial the endpoint of interest Y was replaced by Y ∗. In
the following we will show: a) that βˆY ∗ may be a poor estimator for βY (section 3.1-3.4), and
b) how adjustments to βˆY ∗ using information from the calibration model described by (S2) can
improve inference about the treatment effect (section 4). As a starting point, in the following
section relevant and known properties are defined for the special case that Y ∗ = Y , which is then
followed by the properties under different measurement error structures for Y ∗ in subsequent
sections.
S2.1 No measurement error
Consider the hypothetical case that Y ∗ is a perfect proxy for Y , i.e. Y ∗ = Y . By using that
Y = αY + βYX + ε, as defined in (S1), it follows that:
Y ∗ = αY + βYX + ε.
From standard regression theory (e.g. [40]), we know that if the errors ε satisfy the regular
Gauss-Markov assumptions [40] and their variance is defined by σ2, the OLS estimators βˆ∗Y , αˆ
∗
Y ,
and s2 (defined by S3, S4, and S6, respectively) are Best Linear Unbiased Estimators (BLUE)
for βY , αY , and σ
2, respectively.
Moreover, if the ε are independently and identically (iid) normally distributed, the OLS estima-
tors βˆY ∗ and αˆY ∗ (defined in S3 and S4, respectively) are the Maximum Likelihood Estimators
(MLE) of βY and αY , respectively. Note that the errors ε satisfy the Gauss-Markov assumptions
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if we assume that they are iid normally distributed with mean 0 and constant variance σ2.
Hypotheses for the treatment effect βY , can be defined by
H0 : βY = β0,
HA : βY 6= β0.
Under normality of the error terms ε, the OLS estimator βˆ∗Y defined in (S3) is the MLE for βY
and s2 is an unbiased estimator for σ2, the following is known for the Wald test:
T =
βˆY ∗ − β0√
V̂ar(βˆY ∗)
∼ tN−2, (S7)
where,
V̂ar(βˆY ∗) =
s2∑
i(Xi − X¯)2
. (S8)
Assuming no measurement error in Y and X, under H0, T follows a Student’s t distribution
with N − 2 degrees of freedom [40]. Under HA, T follows a Student’s t distribution with N − 2
degrees of freedom and non-centrality parameter (βY − β0)/
√
V̂ar(βˆY ∗).
S2.2 Classical measurement error
There is classical measurement error in Y ∗ if Y ∗ is an unbiased proxy for Y [10]:
Y ∗ = Y + e, (S9)
where E[e] = 0 and Var(e) = τ 2 and e mutually independent of Y , X, ε (in (S1)).
Using that Y = αY + βYX + ε from (S1), it follows that:
Y ∗ = αY + βYX + ε+ e.
Given the aforementioned assumptions, the sum of e and ε, δ1 = e + ε, has variance Var(δ1) =
σ2 + τ 2. It follows that if the errors δ1 satisfy the Gauss-Markov assumptions, βˆY ∗ in (S3) re-
mains a BLUE estimator for βY . Also, αˆY ∗ in (S4) and s
2 in (S6) remain BLUE estimators for
αY and the variance of δ1, respectively.
Further, if δ1 is iid normally distributed with mean 0 and variance σ
2 + τ 2, then αˆY ∗ is the
MLE for αY and βˆY ∗ is the MLE for βY . Obviously, given that σ
2 > 0 and τ 2 > 0, the vari-
ance of the OLS regression estimator βˆY ∗ is larger if there is classical measurement error in the
outcome compared to the case when there is no measurement error. Under the null hypothesis,
the Wald test-statistic T defined in (S7) still follows a Student’s t distribution with N − 2 de-
grees of freedom. However, under the alternative hypothesis, the non-centrality parameter of T ,
(βY − β0)/
√
V̂ar(βˆY ∗), will be smaller in the presence of classical measurement error.
To summarize, in the presence of only classical measurement error, Type-II error for detect-
ing any given treatment effect increases, Type-I error is unaffected and the treatment effect
estimator is unbiased MLE under standard regularity conditions.
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S2.2.1 Heteroscedastic classical measurement error
In the preceding we assumed that the Gauss-Markov assumptions were met. But notably, in
the case that the variance of the errors e in (S9) varies per treatment arm, the errors are no
longer homoscedastic (as needed to satisfy the Gauss-Markov assumptions) but heteroscedastic.
In the case of this type of heteroscedastic classical measurement error, it can be shown that the
variance of βY ∗ will be underestimated by the default estimator of the variance of βˆY ∗ defined
by (S8), affecting both Type-I and Type-II error.
S2.3 Systematic measurement error
There is systematic measurement error in Y ∗, if Y ∗ systematically depends on Y . Assuming this
dependence is linear, the relation between Y ∗ and Y can be defined as:
Y ∗ = θ0 + θ1Y + e, (S10)
where E[e] = 0 and Var(e) = τ 2. Throughout, we assume systematic measurement error if θ0 6= 0
or θ1 6= 1 (and of course, θ1 6= 0 in all cases). We assume mutual independence between e and
Y , X, ε ( in S1). Naturally, if θ0 = 0 and θ1 = 1 the measurement error is of the classical form.
By using that Y = αY + βYX + ε from (S1), it follows that:
Y ∗ = θ0 + θ1αY + θ1βYX + θ1ε+ e.
Given the aforementioned assumptions, δ2 = θ1ε + e with expected variance θ
2
1σ
2 + τ 2. It fol-
lows that under the Gauss-Markov assumptions, βˆY ∗ defined in (S3) is BLUE for θ1βY , and αˆY ∗
defined in (S4) is BLUE for θ0 + αY and s
2 defined in (S6) is BLUE for the variance of δ2 (i.e.
θ21τ
2 + σ2). Conversely, βˆY ∗ is no longer BLUE for βY . Note that in this case s
2 is BLUE for
θ21σ
2 + τ 2, that is, depending on θ1, smaller or larger than σ
2 (the variance of the error terms if
there is no measurement error).
If we further assume that δ2 is iid normally distributed, we can conclude that αˆY ∗ is the MLE
for θ0 + αY and βˆY ∗ is the MLE for θ1βY . Conversely, βˆY ∗ is no longer the MLE for βY , if there
is systematic measurement error in Y ∗. In the absence of a treatment effect, as θ1βY = 0 if
βY = 0, T defined in (S7) still follows a Student’s t distribution with N − 2 degrees of freedom.
In the presence of any given treatment effect, T follows a non-central Student’s t distribution
with N−2 degrees of freedom and non-centrality parameter (θ1βY −β0)/
√
V̂ar(βˆY ∗). Depending
on the value of θ1, the non-centrality parameter will be smaller or larger than the non-centrality
parameter in the absence of measurement error (see section 3.2).
In summary, if there is systematic measurement error in the endpoints, the Type-I error is
unaffected under standard regularity conditions and hence testing whether there is no effect
is still valid under the null hypothesis [22]). Type-II, however, is affected (it may increase or
decrease) and the treatment effect estimator is a biased MLE.
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S2.4 Differential measurement error
There is differential measurement error in Y ∗ when measurement error varies with X. Assuming
a linear model for this variation, formally:
Y ∗ = θ00 + (θ01 − θ00)X + θ10Y + (θ11 − θ10)XY + eX , (S11)
where E[eX ] = 0 and Var(eX) = τ
2
X and eX independent of the endpoint of interest Y , and ε in
(S1). From the equations it becomes clear that systematic error (equation (S10)) can be seen as
a special case of differential error, where θ00 = θ01 and θ10 = θ11.
By using that Y = αY + βYX + ε from (S1), it follows from equation (S11) that,
Y ∗ = θ00 + θ10αY +
[
θ01 − θ00 + (θ11 − θ10)αY + θ11βY
]
X +
[
θ10 + (θ11 − θ10)X
]
ε+ eX .
Let δ3X =
[
θ10 + (θ11 − θ10)X
]
ε + eX , with expected variance
[
θ210 + (θ
2
11 − θ210)X
]
σ2 + τ 2X .
Since the the error term δ3X is no longer homoscedastic, the OLS estimators defined in (S3)
and (S4) are no longer BLUE. However, the OLS estimator βˆY ∗ in (S3) is consistent (although
not efficient) for θ01 − θ00 + (θ11 − θ10)αY + θ11βY . The OLS estimator αˆY ∗ defined in (S4) is
consistent (although not efficient) for θ00 + θ10αY . Nevertheless, the estimator for the variance
of βˆY ∗ defined in (S8) is no longer valid.
By using the residuals ωi defined in (S6), a heteroscedastic consistent estimator for the vari-
ance of βˆY ∗ is:
V̂ar(βˆY ∗) =
∑
i
[
(Xi − X¯)2ω2i
]
[
∑
i (Xi − X¯)2]2
,
which is known as the White estimator [20]. From standard regression theory, it is known that
using the above defined estimator, T defined in (S7) is still valid. Yet, under differential mea-
surement error no longer
[
θ01− θ00 + (θ11− θ10)αY + θ11βY
]
= 0 if βY = 0. Thus, under the null
hypothesis, T defined in (S7) follows a Student’s t distribution with N − 2 degrees of freedom
and non-centrality parameter (
[
θ01 − θ00 + θ11αY − θ10αY + θ11β0
] − β0)/√V̂ar(βˆY ∗). Conse-
quently, Type-I error changes if there is differential measurement error in Y ∗ and test about
contrast under the null hypothesis are invalid [22]. Moreover, under the alternative hypothesis,
T follows a non-central Student’s t distribution with N−2 degrees of freedom and non-centrality
parameter (
[
θ01− θ00 + (θ11− θ10)αY + θ11βY
]−β0)/√V̂ar(βˆY ∗). Depending on the values of the
θ’s and αY , the non-centrality parameters will be smaller or larger than 0 and the non-centrality
parameter if there is no measurement error, respectively (see section 3.2). Hence, Type-I error
and Type-II error could increase or decrease if there is differential measurement error in Y ∗.
To summarize, Type-I error is not expected nominal (α) if there is differential measurement
error in Y ∗ (see also [22]). Also, similar to systematic error in Y ∗, Type-II error is affected (may
increase or decrease) and the treatment effect estimator is a biased estimator.
S3 Correction methods for measurement error in continuous endpoints
To accommodate measurement error correction, we assume that Y and Y ∗ are both measured for
a smaller set of different individuals not included in the trial (j = 1, . . . , K,K < N), hereinafter
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referred to as the external calibration sample. In all but one case, it is assumed that only Y ∗ and
Y are measured in the external calibration sample. In the case that the error in Y ∗ is different
for the two treatment groups, it is assumed that the external calibration sample is in the form
of a small pilot study where both treatments are allocated (i.e., Y ∗ and Y are both measured
after assignment of X).
S3.1 Systematic measurement error
Using an external calibration set and assuming that the errors e in (S10) are iid normal, the
MLE of the measurement error parameters in (S10) are:
θˆ1 =
∑
j(Y
(c)
j − Y¯ (c))(Y ∗(c)j − Y¯ ∗(c))∑
(Y
(c)
j − Y¯ (c))2
, (S12)
θˆ0 = Y¯
∗(c) − θˆ1Y¯ (c),
t2 =
1
K − 2
∑
j
(Y
∗(c)
j − θˆ0 − θˆ1Y (c)j )2.
The superscript (c) is used to indicate that the measurement is obtained in the calibration set.
From section 3.4, under systematic measurement error and assuming that ε in (S1) and e in
(S10) iid normal and independent, the estimator βˆY ∗ defined in (S3) is the MLE of θ1βY and,
the estimator αˆY ∗ defined in (S4) is the MLE of θ0 + θ1αY . Natural sample estimators for αY
and βY are then
αˆY = (αˆY ∗ − θˆ0)/θˆ1 and βˆY = βˆY ∗/θˆ1, (S13)
where θˆ0 and θˆ1 are the estimated error parameters from the calibration data set. From equation
(S13), it becomes apparent that θˆ1 needs to be assumed bounded away from zero for finite
estimates of αˆY and βˆY [8].
The first moment of estimators αˆY and βˆY can be approximated by using multivariate Taylor
expansions and assuming that (αˆY ∗ , βˆY ∗ , θˆ0, θˆ1) are normally distributed [8],
E[αˆY ] ≈ αY +
[
αY − y¯∗
]
τ 2
θ21S
(c)
yy
and E[βˆY ] ≈ βY + βY τ
2
θ21S
(c)
yy
,
where S
(c)
yy =
∑
(Y
(c)
j − Y¯ (c))2, the total sum of squares of Y (c). In conclusion, the estimators
αˆY and βˆY are consistent. Formal derivations for the presented formulas are provided in the
Appendix.
In the following we will focus on specifying confidence limits for the treatment effect estimator
βˆY defined in (S13). We make use of the fact that this estimator is a ratio, which motivates
the use of the Delta method, Fieller method and Zero-variance method [41]. We also present a
non-parametric bootstrap method for specifying confidence limits [23].
S3.1.1 Delta method
Assuming that βˆY ∗ and θˆ1 are both normally distributed and applying the Delta method, the
second moment of βˆY can be approximated [22]. Formal derivations of the presented formulas
28
L Nab, RHH Groenwold, PMJ Welsing, M van Smeden 29
are provided in Appendix A. The Delta method variance of βˆY is given by:
Var
(
βˆY
) ≈ 1
θ21
[θ21σ2 + τ 2
Sxx
+
β2Y τ
2
S
(c)
yy
]
,
where Sxx =
∑
i(Xi − X¯)2, the total sum of squares of X. An approximation of the above
defined variance, denoted by V̂ar(βˆY ), is provided by approximating θ1, θ
2
1σ
2 + τ 2, τ 2 and βY
respectively by θˆ1, s
2, t2 and βˆY [22].
An approximate confidence interval for the estimator βˆY is then given by
βˆY ± t(α/2,n−2)
√
V̂ar
(
βˆY
)
. (S14)
S3.1.2 Fieller method
A second method to construct confidence intervals for the estimator βˆY in (S13), described by
Buonaccorsi, is the Fieller method [22, 42]. In the case that θˆ1 is significantly different from zero
at a significance level of α (that is, θˆ1/
√
t2/S
(c)
yy > tN−2), the (1− α) confidence intervals of βˆY
are defined by the Fieller method by:
lupper,lower =
βˆY ∗ θˆ1 ±
√
βˆ2Y ∗ θˆ
2
1 − ( t2S(c)yy t
2
q − θˆ21)( s2Sxx t2q − βˆ2Y ∗)
τ2
S
(c)
yy
t2q + θˆ
2
1
. (S15)
A formal derivation can be found in Appendix A.
S3.1.3 Zero-variance method
The zero-variance method adjusts the observed endpoints Y ∗i by
Yˆi = (Y
∗
i − θˆ0)/θˆ1,
where θˆ0 and θˆ1 are derived from (S10). The adjusted endpoints are regressed on the treatment
variable X, which yields,
βˆYˆ =
∑
i(Xi − X¯)(Yˆi − ¯ˆY )∑
i(Xi − X¯)2
=
∑
i(Xi − X¯)(Y ∗i − Y¯ ∗)/θˆ1∑
i(Xi − X¯)2
= βˆY ∗/θˆ1,
αˆYˆ =
¯ˆ
Y − βˆYˆ X¯ =
Y¯ ∗ − βˆY ∗X¯ − θˆ0
θˆ1
= (αˆY ∗ − θˆ0)/θˆ1,
s2
Yˆ
=
1
N − 2
∑
i
(Yˆi − αˆYˆ − βˆYˆXi)2 =
1
θˆ21
s2,
with βˆY ∗ , αˆY ∗ and s
2 as in equations (S3, S4 and S6), respectively. Thus, βˆYˆ equals βˆY and αˆYˆ
equals αˆY defined in (S13).
If the value of θˆ1 (i.e. θ1) is known, the variance of the estimator βˆYˆ is equal to:
Var(βˆYˆ ) = Var(βˆY ∗)/θ
2
1 =
σ2 + τ 2/θ21∑
i (Xi − X¯)2
.
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Using the standard OLS regression framework the variance of βˆYˆ can be estimated by:
V̂ar(βˆYˆ ) =
s2
Yˆ∑
i(Xi − X¯)2
=
s2/θˆ21∑
i(Xi − X¯)2
. (S16)
By replacing θˆ1 by θ1 in the above, the quantity in (S16) is in expectation equal to Var(βˆYˆ )
(defined above). The quantity in (S16) is used in the zero-variance method to construct con-
fidence intervals for βˆYˆ , by replacing V̂ar(βˆYˆ ) for V̂ar(βˆY ) in equation S14. In conclusion, this
zero-variance approach will provide confidence intervals for the treatment effect estimator while
assuming there is no variance in θˆ1 (giving it its name zero-variance method). Although the
zero-variance approach wins in terms of simplicity, it may underestimate the variability of the
ratio since the variance in θˆ1 is assumed zero.
S3.1.4 Bootstrap
An alternative for defining confidence intervals for the corrected treatment effect estimator βˆY
is by using a non-parametric bootstrap [23]. We propose the following stepwise procedure:
1. Draw a random sample with replacement of size K of the calibration sample (Y ∗(c), Y (c))
to estimate θˆ1B defined in (S12).
2. Draw a random sample with replacement of size N of the trial data (Y ∗, X) to calculate
the corrected treatment effect estimate by βˆYB = βY ∗B/θˆ1B . Where βY ∗B is defined in (S3).
3. Repeat step 1-2 B times, with B large (e.g. 999 times).
4. Approximate confidence intervals are given by the (α/2, 1 − α/2) percentile of the distri-
bution of βˆYB .
S3.2 Differential measurement error
For corrections for endpoints that suffer from differential measurement error we will here assume
the existence of a pilot trial, which serves as an external calibration set, where both treatments
are allocated at random that serves as an external calibration set to estimate the measurement
error model in (S11). For notational convenience we rewrite the linear model in equation (S11)
in matrix form as:
Y ∗ = Xθ + e, (S17)
where E(e) = 0 and E(ee′) = Σ, a positive definite matrix, with τ 2X on its diagonal. Further,
θ = (θ1, θ2, θ3, θ4) = (θ00, θ01−θ00, θ10, θ11−θ10). In the external calibration set, the measurement
error parameters θˆ can be estimated by,
θˆ = (X(c)
′
X(c))−1X(c)
′
Y (c), (S18)
with variance,
Var(θˆ) = (X(c)
′
X(c))−1X(c)
′
ΣX(c)(X(c)
′
X(c))−1.
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See [20] for a discussion on different estimators for the above defined variance. From section 2.5
it follows that natural estimators for αY and βY are,
αˆY = (αˆY ∗ − θˆ00)/θˆ10 and βˆY = (βˆY ∗ + αˆY ∗ − θˆ01)/θˆ11 − αˆY , (S19)
where θˆ00, θˆ10, θˆ01 and θˆ11 are estimated from the external calibration set. Here it is assumed
that both θˆ10 and θˆ11 are bounded away from zero (for reasons similar to those mentioned in
section 3.1).
By multivariate Taylor expansions, the first moments of the estimators αˆY and βˆY defined in
(S19) can be approximated [22], in the same way as the estimators for systematic measurement
error (section 4.1),
E
[
αˆY
] ≈ αY + 1
θ210
[
αY Var
(
θˆ10
)
+ Cov
(
θˆ00, θˆ10
)]
,
E
[
βˆY
] ≈ βY + 1
θ211
[
(βY + αY )Var
(
θˆ11
)
+ Cov
(
θˆ01, θˆ11
)]
− 1
θ210
[
αY Var
(
θˆ10
)
+ Cov
(
θˆ00, θˆ10
)]
.
From this, it is apparent that the estimators αˆY and βˆY defined in (S19) are consistent (details are
found in the Appendix). In the subsequent sections we review the Delta method, zero-variance
and propose a bootstrap for specifying confidence limits for the estimator of the treatment effect
under differential measurement error of the endpoints.
S3.2.1 Delta method
The variance of the estimator βˆY defined in (S19) can be approximated by the Delta method
[22]:
Var
(
βˆY
) ≈ 1
θ211
[(
βY + αY
)2
Var
(
θˆ11
)
+ Var
(
βˆY ∗
)
+ Var
(
αˆY ∗
)
+
2Cov
(
αˆY ∗ , βˆY ∗
)
+ Var
(
θˆ01
)
+ 2
(
βY + αY
)
Cov
(
θˆ11, θˆ01
)]
+
Var
(
αˆY
)
,
where Var
(
αˆY
)
is approximated by:
Var
( αˆY ∗ − θˆ00
θˆ10
) ≈ 1
θ210
[
Var
(
αˆY ∗
)
+ α2Y Var
(
θˆ10
)
+ Var
(
θˆ00
)
+ 2αY Cov
(
θˆ00, θˆ10
)]
.
An approximate confidence interval for the estimator βˆY in (S19) is:
βˆY ± t(α/2,n−2)
√
Var
(
βˆY
)
. (S20)
An approximation of θ11, θ10, θ
2
11σ
2 + τ 21 , θ
2
10σ
2 + τ 20 , τ
2
1 , τ
2
0 , βY and αY in the above is provided
by: θˆ11, θˆ10, s
2
1, s
2
0, t
2
1, t
2
0, βˆY and αˆY [22].
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S3.2.2 Zero-variance method
The zero-variance method adjusts the observed endpoints Y ∗i by
Yˆix = (Y
∗
ix − θˆ0x)/θˆ1x,
for x ∈ {0, 1} and θˆ0x) and θˆ1x derived from (S18). In the zero-variance method the above defined
adjusted values are regressed on the treatment variable X, yielding in estimators αˆYˆ and βˆYˆ ,
which are, respectively, equal to the estimators αˆY and βˆY defined in (S19). The variance of these
estimators can be approximated with a heteroscedastic consistent covariance estimator (see [20]
for an overview). Confidence intervals for βˆYˆ are subsequently constructed by using formula S20.
Similar to what is described in section 4.1.3 discussing the zero-variance method for systematic
measurement error, this way of constructing confidence intervals neglects the variance of the
θ’s from the calibration data set, and will thus often yield in confidence intervals that are too
narrow.
S3.2.3 Bootstrap
We here alternatively propose a non-parametric bootstrap procedure to specify confidence limits.
This entails the following steps:
1. Draw a random sample with replacement of size K of the calibration sample and estimate
θˆ as defined in (S18).
2. Draw a random sample (with replacement) of size N of the study population and calculate
the effect estimate by αˆYB = (αY ∗B − θˆ00B)/θˆ10B and βˆYB = (βY ∗B + αY ∗B − θˆ01B)/θˆ11B − αˆYB .
Where βY ∗B and αY ∗B are defined in (S3) and (S4), respectively.
3. Repeat step 1-2 B times, with B large (e.g. 999 times).
4. Approximate confidence intervals are given by the (α/2, 1 − α/2) percentile of the distri-
bution of βˆYB .
S4 Measurement error depending on prognostic factors
Suppose that there is a prognostic factor S, and assume that, E[Y |X,S] = αY + βYX + γY S,
E[Y ∗|Y, S] = Y + ζS, Y ∗ |= X|Y (non-differential measurement error) and S |= X (randomization
is well-performed).
Suppose we want to estimate the effect of Y on X (i.e., βY ), but instead of Y we have only mea-
sured the with measurement error contaminated Y ∗. If one is aware that there is a prognostic
factor that confounds the relation between Y ∗ and Y (and this factor is measured), one could
decide to regress Y ∗ on X and S. The regression of Y ∗ on X and S equals,
E[Y ∗|X,S] = EY |X,S{EY∗|X,S,Y[Y∗|X, S,Y]|X, S}
= EY |X,S{EY∗|S,Y[Y∗|S,Y]|X, S}
= EY |X,S{Y + ζS|X, S}
= αY + βYX + (γY + ζ)S.
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Thus, using the with measurement error contaminated endpoint Y ∗ instead of the preferred
endpoint Y will provide an unbiased estimation of βY .
However, if one is not aware of the prognostic factor, one might naively regress Y ∗ on X,
which equals:
E[Y ∗|X] = ES|X{EY |X,S{EY∗|X,S,Y[Y∗|X, S,Y]|X, S}|X}
= ES|X{αY + βYX + (γY + ζ)S|X}
= αY + βYX + (γY + ζ)E[S].
In conclusion, by ignoring the prognostic factor and using the with measurement error contam-
inated endpoint Y ∗ instead of the preferred endpoint Y , the regression of Y ∗ on X still results
in an unbiased estimation of βY .
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A1 Approximation of bias and variance in corrected estimator
A1.1 Systematic measurement error
Obvious estimators for αY and βY are:
αˆY = (αˆY ∗ − θˆ0)/θˆ1 and βˆY = βˆY ∗/θˆ1.
These estimators can be approximated with a second order Taylor expansion by:
βˆY ∗
θˆ1
≈ βY ∗
θ1
− βY ∗
θ21
(θˆ1 − θ1) + 1
θ1
(βˆY ∗ − βY ∗)
+
1
2!
[2βY ∗
θ31
(θˆ1 − θ1)2 − 2
θ21
(θˆ1 − θ1)(βˆY ∗ − βY ∗)
]
,
αˆY ∗
θˆ1
≈ αY ∗
θ1
− αY ∗
θ21
(θˆ1 − θ1) + 1
θ1
(αˆY ∗ − αY ∗)
+
1
2!
[2αY ∗
θ31
(θˆ1 − θ1)2 − 2
θ21
(θˆ1 − θ1)(αˆY ∗ − αY ∗)
]
,
θˆ0
θˆ1
≈ θ0
θ1
− θ0
θ21
(θˆ1 − θ1) + 1
θ1
(θˆ0 − θ0)
+
1
2!
[2θ0
θ31
(θˆ1 − θ1)2 − 2
θ21
(θˆ1 − θ1)(θˆ0 − θ0)
]
.
Simplifying these terms and substraction of the latter two, will lead to the following approxima-
tions for αˆY and βˆY :
βˆY ∗
θˆ1
≈ βY ∗
θ1
+
1
θ1
[
− βY ∗
θ1
(θˆ1 − θ1) + (βˆY ∗ − βY ∗)
]
+
1
θ21
[βY ∗
θ1
(θˆ1 − θ1)2 − (βˆY ∗ − βY ∗)(θˆ1 − θ1)
]
,
αˆY ∗ − θˆ0
θˆ1
≈ αY ∗ − θ0
θ1
+
1
θ1
[
− αY ∗ − θ0
θ1
(θˆ1 − θ1) + (αˆY ∗ − αY ∗)− (θˆ0 − θ0)
]
+
1
θ21
[αY ∗ − θ0
θ1
(θˆ1 − θ1)2 − (αˆY ∗ − αY ∗)(θˆ1 − θ1) + (θˆ0 − θ0)(θˆ1 − θ1)
]
.
Since E[θˆ1 − θ1] = 0, E[θˆ0 − θ0] = 0, E[αˆY ∗ − αY ∗ ] = 0 and E[βˆY ∗ − βY ∗ ] = 0 an approximation
of the expected value of the estimator αˆY is given by:
E
[ αˆY ∗ − θˆ0
θˆ1
] ≈ αY ∗ − θ0
θ1
+
1
θ21
[αY ∗ − θ0
θ1
E
[
(θˆ1 − θ1)2
]
− E[(αˆY ∗ − αY ∗)(θˆ1 − θ1)]+ E[(θˆ0 − θ0)(θˆ1 − θ1)]] =
=
αY ∗ − θ0
θ1
+
1
θ21
[αY ∗ − θ0
θ1
Var
(
θˆ1
)− Cov(αˆY ∗ , θˆ1)+ Cov(θˆ0, θˆ1)] =
= αY +
1
θ21
[ τ 2[αY − Y¯ (c)]∑
(Y
(c)
j − Y¯ (c))2
]
.
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Congruently, an approximation of the expected value of the estimator βˆY is given by:
E
[ βˆY ∗
θˆ1
] ≈ βY ∗
θ1
+
1
θ21
[βY ∗
θ1
E
[
(θˆ1 − θ1)2
]− E[(βˆY ∗ − βY ∗)(θˆ1 − θ1)]] =
=
βY ∗
θ1
+
1
θ21
[βY ∗
θ1
Var
(
θˆ1
)]
=
= βY +
1
θ21
[ τ 2βY∑
(Y
(c)
j − Y¯ (c))2
]
.
Only using the first order Taylor expansion of the estimators, approximations of the variance of
αˆY and βˆY are respectively:
Var
( αˆY ∗ − θˆ0
θˆ1
) ≈ 1
θ21
[
α2Y Var
(
θˆ1
)
+ Var
(
αˆY ∗ − θˆ0
)− 2αY Cov(θˆ1, αˆY ∗ − θˆ0)] =
=
1
θ21
[
α2Y Var
(
θˆ1
)
+ Var
(
αˆY ∗
)
+ Var
(
θˆ0
)− 2Cov(αˆY ∗ , θˆ0)
− 2αY Cov
(
θˆ1, αˆY ∗
)
+ 2αY Cov
(
θˆ1, θˆ0
)]
=
=
1
θ21
[(θ21σ2 + τ 2)∑X2i
N
∑
(Xi − X¯)2 + α
2
Y
τ 2∑
(Y
(c)
j − Y¯ (c))2
+
τ 2
∑
(Y
(c)
j )
2
K
∑
(Y
(c)
j − Y¯ (c))2
+ 2αY
−τ 2Y¯ (c)∑
(Y
(c)
j − Y¯ (c))2
]
=
=
1
θ21
[(θ21σ2 + τ 2)∑X2i
N
∑
(Xi − x¯)2 + α
2
Y
τ 2∑
(y
(c)
j − y¯(c))2
+
τ 2(
∑
(y
(c)
j − y¯(c))2 +K(y¯(c))2)
K
∑
(y
(c)
j − y¯(c))2
− 2αY τ
2y¯(c)∑
(y
(c)
j − y¯(c))2
]
=
=
1
θ21
[(θ21σ2 + τ 2)∑x2i
N
∑
(xi − x¯)2 + τ
2
( 1
K
+
(y¯(c) − αY )2∑
(y
(c)
j − y¯(c))2
)]
,
Var
( βˆY ∗
θˆ1
) ≈ 1
θ21
[ θ21σ2 + τ 2∑
(xi − x¯)2 +
β2Y τ
2∑
(y
(c)
j − y¯(c))2
]
.
A1.1.1 Fieller method
Assume that βˆY ∗ and θˆ1 are normally distributed (note that this assumption is satisfied with large
study samples (N) and large calibration samples (K)). The sum of two normally distributed
variables is normally distributed, hence, βˆY ∗ − βY θˆ1 is normally distributed.
Furthermore, we have
Var(βˆY ∗ − βY θˆ1) = Var(βˆY ∗) + β2Y Var(θˆ1).
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Where,
Var(βˆY ∗) =
θ21σ
2 + τ 2∑
(xi − x¯)2
Var(θˆ1) =
τ 2∑
(y
(c)
j − y¯(c))2
If we now divide the term βˆY ∗ − βY θˆ1 by its standard deviation, we get:
T0 =
βˆY ∗ − βY θˆ1√
θ21σ
2+τ2∑
(xi−x¯)2 +
τ2∑
(y
(c)
j −y¯(c))2
β2Y
(A1)
We are interested to find the set of βY values for which the corresponding T0 values lie within
the (1 − α) quantiles of the t-distribution with N − 2 degrees of freedom (this only holds ap-
proximately, see for details [41]). Let us denote these values by tq, from (A1) we have,
(
τ 2∑
(y
(c)
j − y¯(c))2
t2q − θˆ21)β2Y + 2βˆY ∗ θˆ1βY + (
θ21σ
2 + τ 2∑
(xi − x¯)2 t
2
q − βˆ2Y ∗) = 0.
In the case that θˆ1 is significantly different from zero at a significance level of α (that is,
θˆ1/
√
τ2∑
(y
(c)
j −y¯(c))2
> tq), solving this for βY results in the following (1− α) confidence intervals:
βY =
−βˆY ∗ θˆ1 ±
√
βˆ2Y ∗ θˆ
2
1 − ( τ2∑(y(c)j −y¯(c))2 t2q − θˆ21)(
θ21σ
2+τ2∑
(xi−x¯)2 t
2
q − βˆ2Y ∗)
τ2∑
(y
(c)
j −y¯(c))2
t2q − θˆ21
.
In the other case, the confidence intervals are unbounded, see for more details [41].
A1.2 Differential measurement error
Obvious estimators for αY and βY are:
αˆY = (αˆY ∗ − θˆ00)/θˆ10 and βˆY = (βˆY ∗ + αˆY ∗ − θˆ01)/θˆ11 − αˆY .
These estimators can be approximated with a second order Taylor expansion by:
αˆY ∗ − θˆ00
θˆ10
≈ αY ∗ − θ00
θ10
+
1
θ10
[
− αY ∗ − θ00
θ10
(θˆ10 − θ10) + (αˆY ∗ − αY ∗)− (θˆ00 − θ00)
]
+
1
θ211
[αY ∗ − θ00
θ10
(θˆ10 − θ10)2 − (αˆY ∗ − αY ∗)(θˆ10 − θ10) + (θˆ00 − θ00)(θˆ10 − θ10)
]
,
βˆY ∗ − θˆ01
θˆ11
≈ βY ∗ − θ01
θ11
+
1
θ11
[
− βY ∗ − θ01
θ11
(θˆ11 − θ11) + (βˆY ∗ − βY ∗)− (θˆ01 − θ01)
]
+
1
θ211
[βY ∗ − θ01
θ11
(θˆ11 − θ11)2 − (βˆY ∗ − βY ∗)(θˆ11 − θ11) + (θˆ01 − θ01)(θˆ11 − θ11)
]
,
αˆY ∗
θˆ11
≈ αY ∗
θ11
+
1
θ11
[
− αY ∗
θ11
(θˆ11 − θ11) + (αˆY ∗ − αY ∗))
]
+
1
θ211
[αY ∗
θ11
(θˆ11 − θ11)2 − (αˆY ∗ − αY ∗)(θˆ11 − θ11)
]
.
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Congruent to the results for the estimators under systematic measurement error, we can con-
clude:
E
[ αˆY ∗ − θˆ00
θˆ10
] ≈ αY + 1
θ210
[
αY Var
(
θˆ10
)
+ Cov
(
θˆ00, θˆ10
)]
.
Congruently, an approximation of the expected value of the estimator βˆY is given by:
E
[ βˆY ∗ + αˆY ∗ − θˆ01
θˆ11
− αˆY
] ≈ βY + 1
θ211
[
(βY + αY )Var
(
θˆ11
)
+ Cov
(
θˆ01, θˆ11
)]
− 1
θ210
[
αY Var
(
θˆ10
)
+ Cov
(
θˆ00, θˆ10
)]
.
And the variance of the estimators is approximated by:
Var
( αˆY ∗ − θˆ00
θˆ10
) ≈ 1
θ210
[
Var
(
αˆY ∗
)
+ α2Y Var
(
θˆ10
)
+ Var
(
θˆ00
)
+ 2αY Cov
(
θˆ00, θˆ10
)]
,
Var
( βˆY ∗ + αˆY ∗ − θˆ01
θˆ11
− αˆY
) ≈ 1
θ211
[(
βY + αY
)2
Var
(
θˆ11
)
+ Var
(
βˆY ∗
)
+ Var
(
αˆY ∗
)
+ 2Cov
(
αˆY ∗ , βˆY ∗
)
+ Var
(
θˆ01
)
+ 2
(
βY + αY
)
Cov
(
θˆ11, θˆ01
)]
+ Var
(
αˆY
)
.
Note that in the case of differential measurement error, we assume that Cov
(
θˆ11, θˆ00) = 0,
Cov
(
θˆ11, θˆ10) = 0, Cov
(
θˆ01, θˆ00) = 0 and Cov
(
θˆ01, θˆ10) = 0.
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